When Is It Time for a Chief Regulatory Officer?

The gap between a regulatory affairs lead and regulatory leadership rarely announces itself. It becomes visible at a board meeting, a fundraise, or a major agency interaction — when the stakes are high enough to expose what was missing all along. The distinction has nothing to do with title and everything to do with scope: the ability to shape development strategy, engage health authorities as a strategic partner, and represent the regulatory position at the level the moment demands. 

The signals are almost always present before the gap becomes expensive, at the last financing, at the previous agency interaction, in the cross-functional decisions made without a senior regulatory voice. The question is whether the leadership team is looking for them. 

The most common version of this gap is a regulatory function that is single-threaded: one person who is simultaneously the strategist, the executor, the agency relationship manager, and the internal regulatory voice across clinical, Chemistry, Manufacturing and Controls (CMC), and safety. That person is almost always capable. That person is stretched to the point where strategic thinking has been crowded out by execution. Execution fills the week. The strategic work has no hard deadline and gets pushed every time, until the cost of that becomes impossible to ignore. 

The gap also shows up in what does not happen. A clinical team proposes a protocol amendment. The regulatory implications, what it means for the label, for the agency's expectations, for the submission timeline are never surfaced, because no one in the room holds that view. The decision gets made. The consequences arrive later. 

This is the predictable result of asking one person to hold two jobs simultaneously, strategic leadership and operational execution,  with no structural support for either. The operational job has consequences that are immediate and visible. The strategic consequences are equally real, just delayed long enough to be mistaken for something else when they finally arrive.  

The trigger moments that expose a regulatory leadership gap typically cluster around fundraising, a major health authority interaction, or the point at which a development decision made without adequate regulatory input begins to generate consequences. Each moment differs in what it reveals and what it costs. 

Fundraising is often the first moment when investors or potential acquirers begin asking detailed questions about regulatory strategy; pathway rationale, risk mitigation, agency engagement history or the logic connecting the evidence package to the intended label. The answers reveal whether the regulatory thinking has kept pace with the program's ambition. A regulatory affairs lead focused on execution can describe what has been done. A regulatory leader can explain why it was done, what it means for the path ahead, and where the genuine risks sit. Investors hear the difference, and it shows up in the confidence reflected in term sheets. 

A major health authority interaction, a pre-IND meeting with the FDA, a scientific advice request to the EMA, or an end-of-phase discussion requires someone who can own the strategy behind the meeting, not just the preparation of the briefing document. The questions the company asks, the way the evidence is framed, the fallback positions prepared for each scenario reflects whether someone with senior regulatory judgment shaped the approach or whether the team prepared the mechanics and hoped the strategy would take care of itself.

Once the leadership team recognizes the gap, the next decision is which model fits. Here's where many companies default to what feels most familiar rather than what the situation actually requires. 

If the gap is strategic direction without execution capacity, a fractional Chief Regulatory Officer is often the right fit. This model provides executive-level judgment right-sized for the stage, without the overhead of a premature full-time hire. It is more accurately understood as a staging decision than a cost measure: the company gets the leadership it needs now, at the scope it needs now, with the flexibility to evolve as the program matures. 

If the gap is caused by a leadership transition; a departure, a hire that has not closed, a restructuring, an interim Chief Regulatory Officer provides continuity and momentum without requiring a permanent decision under time pressure. Programs do not pause for hiring timelines, and the cost of a leadership vacuum during a critical development window is almost always higher than the cost of interim coverage. 

If the gap spans both strategy and hands-on execution, common in very lean teams approaching a high-stakes milestone, an embedded model that combines strategic leadership with direct program contribution is more appropriate. Someone who can set the regulatory direction and also move the work forward day to day, because at this stage the company cannot afford to separate those two functions. 

And for companies that have a regulatory leader already stretching into Chief Regulatory Officer scope without the full support structure that role requires, targeted senior support can strengthen the function without replacing it. This is not about bringing in someone above the existing leader. It is about giving that leader the strategic backing, the governance frameworks, and the executive-level sounding board they need to succeed in a role that has outgrown its original design. 

For biotech companies with global ambitions, regulatory leadership requires genuine depth in each regulatory environment the program will navigate. A leader experienced in FDA processes but not the EMA will make strategic assumptions about evidence standards, engagement philosophy, and labeling expectations that do not transfer and the gap typically surfaces during a major EMA interaction or a licensing partner's diligence process. 

Everything above applies with greater force when the program has global ambitions. FDA and EMA programs require meaningfully different regulatory leadership profiles, and the difference cannot be bridged by reading EMA guidance documents. 

A regulatory leader with deep FDA experience, but limited EMA depth will make strategic assumptions about evidence standards, about agency engagement philosophy, or about labeling expectations that do not translate. EMA engagement is consultative in ways that FDA engagement is not. The scientific advice process, the rapporteur relationship, the way the Committee for Medicinal Products for Human Use (CHMP) assesses benefit-risk require a depth of understanding that comes from having navigated them. The assumptions that produce a strong FDA strategy can produce a weak EMA strategy, and the company may not discover the difference until a scientific advice procedure returns feedback that challenges the entire development plan. 

If they do not, the global strategy carries a structural weakness. It will surface at the worst possible moment; during a major EMA interaction, when a global licensing partner begins its own diligence, or when the company realizes that the evidence package designed for the FDA does not answer the questions the EMA will ask. 

The question of when to bring in a Chief Regulatory Officer is almost always answered too late. The signals were present earlier: at the last board meeting, at the last agency interaction, in the last cross-functional decision made without a senior regulatory voice. 

SSI Strategy works with biotech leadership teams to close that gap; through fractional, interim, and embedded regulatory leadership models designed to match the company's stage, the program's complexity, and the milestones ahead. 

If you are sensing the gap between where your regulatory function is and where your program needs it to be, explore how SSI approaches regulatory leadership.